Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors With Cognitive Impairment
Zachary A. Marcum, Jordana B. Cohen, Chong Zhang, et al.
JAMA Network Open (2022) Vol. 5, Iss. 1, pp. e2145319-e2145319
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Connie W. Tsao, Aaron W. Aday, Zaid Almarzooq, et al.
Circulation (2023) Vol. 147, Iss. 8
Open Access | Times Cited: 4252
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension
Giuseppe Mancia, Reinhold Kreutz, Mattias Brunström, et al.
Journal of Hypertension (2023) Vol. 41, Iss. 12, pp. 1874-2071
Open Access | Times Cited: 1600
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Seth S. Martin, Aaron W. Aday, Zaid Almarzooq, et al.
Circulation (2024) Vol. 149, Iss. 8
Open Access | Times Cited: 934
Hypertension, Neurovascular Dysfunction, and Cognitive Impairment
Monica M. Santisteban, Costantino Iadecola, Daniela Carnevale
Hypertension (2022) Vol. 80, Iss. 1, pp. 22-34
Open Access | Times Cited: 128
Hypertension, Neurodegeneration, and Cognitive Decline
Anthony G. Pacholko, Costantino Iadecola
Hypertension (2024) Vol. 81, Iss. 5, pp. 991-1007
Closed Access | Times Cited: 30
High-Throughput Screening for Prescribing Cascades Among Real-World Angiotensin-II Receptor Blockers (ARBs) Initiators
Asinamai Ndai, Kayla Smith, Shailina Keshwani, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access | Times Cited: 1
Angiotensin Receptor Blockers Are Associated With a Lower Risk of Progression From Mild Cognitive Impairment to Dementia
Zhenhong Deng, Jingru Jiang, Jia Wang, et al.
Hypertension (2022) Vol. 79, Iss. 10, pp. 2159-2169
Open Access | Times Cited: 31
Neuroprotective effect of angiotensin II receptor blockers on the risk of incident Alzheimer’s disease: A nationwide population-based cohort study
Hyun Woo Lee, Seung Yeon Kim, Youngkwon Jo, et al.
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 22
The 2021 yearbook of Neurorestoratology
Hari Shanker Sharma, Michael Chopp, Lin Chen, et al.
Journal of Neurorestoratology (2022) Vol. 10, Iss. 3, pp. 100008-100008
Open Access | Times Cited: 27
Association of New Use of Antihypertensives That Stimulate vs Inhibit Type 2 and 4 Angiotensin II Receptors With Dementia Among Medicare Beneficiaries
Zachary A. Marcum, Nico Gabriel, Adam P. Bress, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2249370-e2249370
Open Access | Times Cited: 16
Angiotensin Receptor Blockers and Cognition: a Scoping Review
Zhen Zhou, Suzanne G. Orchard, Mark Nelson, et al.
Current Hypertension Reports (2023) Vol. 26, Iss. 1, pp. 1-19
Open Access | Times Cited: 15
Antihypertensive medication classes and risk of incident dementia in primary care patients: a longitudinal cohort study in the Netherlands
Jakob L. Schroevers, Marieke P. Hoevenaar‐Blom, Wim B. Busschers, et al.
The Lancet Regional Health - Europe (2024) Vol. 42, pp. 100927-100927
Open Access | Times Cited: 4
Antihypertensive Medication Class and Functional Outcomes After Nonlobar Intracerebral Hemorrhage
Mohamed Ridha, James Burke, Padmini Sekar, et al.
JAMA Network Open (2025) Vol. 8, Iss. 2, pp. e2457770-e2457770
Open Access
Blood pressure and the brain: the conundrum of hypertension and dementia
Rebecca F. Gottesman, Marco Egle, Renée C. Groechel, et al.
Cardiovascular Research (2025)
Closed Access
Comparative effects of angiotensin II stimulating and inhibiting antihypertensives on dementia risk: a systematic review and meta-analysis
Eyayaw Ashete Belachew, Gregory M. Peterson, Woldesellassie M. Bezabhe
GeroScience (2025)
Open Access
Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer’s disease
Ihab Hajjar, Maureen Okafor, Limeng Wan, et al.
Brain Communications (2022) Vol. 4, Iss. 6
Open Access | Times Cited: 16
Clinical guidelines of the Russian Medical Society on arterial Hypertension (RSH) and the Eurasian association of Cardiologists (EaC) for the diagnosis and treatment of arterial hypertension (2024)
И Е Чазова, Н М Чихладзе, N. V. Blinova, et al.
Systemic Hypertension (2024) Vol. 21, Iss. 4, pp. 5-110
Open Access | Times Cited: 2
The Role of Vascular Risk Factors in Cognitive Impairment and Dementia and Prospects for Prevention
Simin Mahinrad, Farzaneh A. Sorond, Philip B. Gorelick
Clinics in Geriatric Medicine (2022) Vol. 39, Iss. 1, pp. 123-134
Closed Access | Times Cited: 9
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Connie W. Tsao, Aaron W. Aday, Zaid Almarzooq, et al.
Circulation (2023) Vol. 147, Iss. 8
Closed Access | Times Cited: 4
Cardiometabolic health, menopausal estrogen therapy and the brain: How effects of estrogens diverge in healthy and unhealthy preclinical models of aging
Jill M. Daniel, Sarah H. Lindsey, Ricardo Mostany, et al.
Frontiers in Neuroendocrinology (2023) Vol. 70, pp. 101068-101068
Open Access | Times Cited: 4
Twelve hot questions in the management of hypertension in patients aged 80+ years and their answers with the help of the 2023 European Society of Hypertension Guidelines
Gülistan Bahat, Heloísa Ribeiro, James P. Sheppard, et al.
Journal of Hypertension (2024)
Closed Access | Times Cited: 1
Antihypertensive medication classes and the risk of dementia over a decade of follow-up
Jakob L. Schroevers, Esmé Eggink, Marieke P. Hoevenaar‐Blom, et al.
Journal of Hypertension (2022)
Open Access | Times Cited: 6
Angiotensin-II stimulating vs. inhibiting antihypertensive drugs and the risk of Alzheimer's disease or related dementia in a large cohort of older patients with colorectal cancer
Xianglin L. Du, Zhuoyun Li, Paul E. Schulz
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 2
Can Preferentially Prescribing Angiotensin II Receptor Blockers (ARBs) over Angiotensin-Converting Enzyme Inhibitors (ACEIs) Decrease Dementia Risk and Improve Brain Health Equity?
Zachary A. Marcum, Jordana B. Cohen, Eric B. Larson, et al.
NAM Perspectives (2022), Iss. 5
Open Access | Times Cited: 3
The role of angiotensin peptides in the brain during health and disease
David Zhang, Christopher G. Sobey, T. Michael De Silva
Elsevier eBooks (2023), pp. 749-773
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top